Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 16;10(10):e31315.
doi: 10.1016/j.heliyon.2024.e31315. eCollection 2024 May 30.

Real-world evidence for brolucizumab efficacy in age-related macular degeneration and central serous chorioretinopathy patients

Samoila Lacramioara  1   2 , Samoila Ovidiu  3 , Clichici Simona  1
Affiliations

Real-world evidence for brolucizumab efficacy in age-related macular degeneration and central serous chorioretinopathy patients

Samoila Lacramioara et al. Heliyon. .

Abstract

Real-world studies concerning different populations are valuable and bring new information regarding different regimens of Brolucizumab injections and their adverse reactions. The present study investigates the efficacy of a pro-re-nata regimen (PRN) for neovascular Age-related Macular Degeneration (nAMD). Separate from the main statistics we report the use of Brolucizumab in central serous chorioretinopathy (CSC). A retrospective observational single-center study was conducted on 82 eyes treated with Brolucizumab between 2021 and 2023, for nAMD. Patients were injected at intervals of at least 2 months after the loading phase. In 9 (3-20) months follow-up, only 0.26 % adverse reactions were noticed, with good resolution of retinal fluid (significant reduction of CST on SD-OCT, -72.50μ, p < 0.05), especially for subretinal fluid. 54 % of the eyes remained fluid-free. The interval of injection (INTOI, a parameter calculated by averaging the results of the division of the follow-up period to the number of injections received by each patient) was 2.68 (corresponding to an injection interval of 11 weeks). This could become an important parameter for the characterization of Brolucizumab and any other anti-VEGF therapy and could provide a more precise interval of injection in the future. Four patients also received Brolucizumab for the treatment of chronic CSC (3 doses each). All showed good response, 3 of them remaining fluid-free.

Keywords: Age-related macular degeneration; Brolucizumab; Central serous chorioretinopathy; Interval of injection; Intraocular inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Pretreatment (blue) versus naïve (red): OCT variation. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2
Fig. 2
Four patients with chronic CSC, before (left) and after (right) injection with Brolucizumab (OCT and OCTA images).
See this image and copyright information in PMC

References

    1. Fabre M., Mateo L., Lamaa D., Baillif S., Pagès G., Demange L., Ronco C., Benhida R. Recent advances in age-related macular degeneration therapies. Molecules. 2022;27(16):5089. - PMC - PubMed
    1. Silvestri G., Williams M.A., McAuley C., Oakes K., Sillery E., Henderson D.C., Ferguson S., Silvestri V., Muldrew K.A. Drusen prevalence and pigmentary changes in Caucasians aged 18-54 years. Eye. 2012;26(10):1357–1362. - PMC - PubMed
    1. Williams M.A., Craig D., Passmore P., Silvestri G. Retinal drusen: harbingers of age, safe havens for trouble. Age Ageing. 2009;6(38):648–654. - PubMed
    1. Colijn J.M., Buitendijk G.H.S., Prokofyeva E., Alves D., Cachulo M.L., Khawaja A.P., Cougnard-Gregoire A., Merle B.M.J., Korb C., Erke M.G., Bron A., Anastasopoulos E., Meester-Smoor M.A., Segato T., Piermarocchi S., de Jong P.T.V.M., Vingerling J.R., Topouzis F., Creuzot-Garcher C., Bertelsen G., Pfeiffer N., Fletcher A.E., Foster P.J., Silva R., Korobelnik J.F., Delcourt C., Klaver C.C.W., EYE-RISK consortium; European Eye Epidemiology (E3) consortium Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology. 2017;124(12):1753–1763. - PMC - PubMed
    1. Kim L.A., D'Amore P.A. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am. J. Pathol. 2012;181(2):376–379. - PMC - PubMed

LinkOut - more resources